Fused imidazo-piperidine JAK inhibitor compound
US11160810B2 · kind B2 · utility
2Cited by
14References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2019 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Jun 2, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.